-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110

Benzinga·03/17/2026 13:32:08
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and raises the price target from $105 to $110.